102791-87-7

Basic information

• Product Name: 4-(4-Methyl-1H-imidazol-1-yl)benzenamine
• Synonyms: 4-(4-Methyl-1H-imidazol-1-yl)benzenamine;4-(4-methylimidaole)benzenamine;1-(4-Aminophenyl)-4-methyl-1H-imidazole;1-(4-Aminophenyl)-4-methylimidazole;4-(4-Methylimidazol-1-yl)phenylamine
• CAS NO: 102791-87-7
• Molecular Formula: C₁₀H₁₁N₃
• Molecular Weight: 173.21444
• Product Categories: Imidazol&Benzimidazole
• Mol File: 102791-87-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 367.586 °C at 760 mmHg
• Flash Point: 176.11 °C
• Appearance: Kind of white to yellow powder
• Density: 1.17
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.625
• Storage Temp.: 2-8°C
• PKA: 6.55±0.61(Predicted)
• CAS DataBase Reference: 4-(4-Methyl-1H-imidazol-1-yl)benzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Methyl-1H-imidazol-1-yl)benzenamine(102791-87-7)
• EPA Substance Registry System: 4-(4-Methyl-1H-imidazol-1-yl)benzenamine(102791-87-7)

Safety Data

• Hazardous Substances Data: 102791-87-7(Hazardous Substances Data)

Usage

Description

4-(4-Methyl-1H-imidazol-1-yl)benzenamine is an organic compound with the molecular formula C14H14N2. It is characterized by the presence of an imidazole ring and an amine group, which contribute to its chemical properties and potential applications.

Uses

Used in Pharmaceutical Industry:
4-(4-Methyl-1H-imidazol-1-yl)benzenamine is used as a chemical intermediate for the preparation of substituted N-?phenyl-?4-?aryl-?2-?pyrimidinamines. These compounds are known as mediator release inhibitors, which can be utilized in the development of drugs targeting various medical conditions, such as inflammation and allergic reactions.

InChI:InChI=1/C10H11N3/c1-8-6-13(7-12-8)10-4-2-9(11)3-5-10/h2-7H,11H2,1H3

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 90946-21-7 4-methyl-1-(4-nitrophenyl)-1H-imidazole 

Downstream Products

• 1300695-70-8 1,1-dimethylethyl (3-{[4-(4-methyl-1H-imidazol-1-yl)phenyl]amino}butanoyl)carbamate 
• 1201902-19-3 [6-(4-methyl-1H-imidazol-1-yl)-2-(phenyl)]quinoline 
• 1240608-23-4 2-(4-fluorophenyl)-1-methyl-N-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-1H-benzimidazol-4-amine 
• 1201902-62-6 3-ethoxy-N-[4-(4-methyl-1H-imidazol-1-yl)phenyl]acrylamide 
• 1079169-51-9 C₂₂H₂₆N₄O 

Relevant articles and documents

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

FUSED MORPHOLINOPYRIMIDINES AND METHODS OF USE THEREOF

The present disclosure relates to Fused Morpholinopyrimidines, pharmaceutical compositions comprising an effective amount of a Fused Morpholinopyrimidine and methods for using a Fused Morpholinopyrimidine in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of a Fused Morpholinopyrimidine.

THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS

Tetrahydroquinoline compounds of formula (I) or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.